AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.
Share
Why It Matters
AtriCure did better than people expected in the latest quarter. The company raised its money goals for next year, which usually means good things ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.